# Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

> **NCT00516217** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 30 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** galiximab

## Key facts

- **NCT ID:** NCT00516217
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2011-09
- **Final completion:** 2015-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00516217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00516217, "Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00516217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*